Limits...
Economic impact of disease progression in follicular non-Hodgkin lymphoma.

Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C - Leuk. Lymphoma (2011)

Bottom Line: Costs per patient per month (PPPM) were compared between patients with PD versus non-PD.Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not.The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Healthcare Informatics, US Oncology, Houston, TX 77380, USA. roy.beveridge@usoncology.com

ABSTRACT
Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.

Show MeSH

Related in: MedlinePlus

Cumulative 12-month total cost by progression status.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3211193&req=5

fig1: Cumulative 12-month total cost by progression status.

Mentions: Figure 1 shows the cumulative total cost over 12 months by progression status. The cumulative 6-month total cost for patients with PD was $21 621 vs. $5226 for non-PD patients. At 12-months, the cumulative total cost for patients with PD was $30 890 vs. $8704 for non-PD patients. Table III presents a comparison of mean costs PPPM by progression status. Average costs PPPM over the 6-month follow-up period for patients with PD were $2667 more than for non-PD patients (p < 0.001), with a relative cost four times higher. Differences in cost were significant in all categories.


Economic impact of disease progression in follicular non-Hodgkin lymphoma.

Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C - Leuk. Lymphoma (2011)

Cumulative 12-month total cost by progression status.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3211193&req=5

fig1: Cumulative 12-month total cost by progression status.
Mentions: Figure 1 shows the cumulative total cost over 12 months by progression status. The cumulative 6-month total cost for patients with PD was $21 621 vs. $5226 for non-PD patients. At 12-months, the cumulative total cost for patients with PD was $30 890 vs. $8704 for non-PD patients. Table III presents a comparison of mean costs PPPM by progression status. Average costs PPPM over the 6-month follow-up period for patients with PD were $2667 more than for non-PD patients (p < 0.001), with a relative cost four times higher. Differences in cost were significant in all categories.

Bottom Line: Costs per patient per month (PPPM) were compared between patients with PD versus non-PD.Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not.The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Healthcare Informatics, US Oncology, Houston, TX 77380, USA. roy.beveridge@usoncology.com

ABSTRACT
Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.

Show MeSH
Related in: MedlinePlus